|
|
Post by hellodolly on May 10, 2024 6:01:50 GMT -5
Thinly traded PM but up nearly 10% +.39 Edit +12% .53 |
|
|
|
Post by prcgorman2 on May 10, 2024 7:11:39 GMT -5
7 years in a CEO position where much compensation is stock issued from the treasury with a par value of 1 cent (typically) and where the CEO’s net worth appreciates if the CEO performs well and performance is the basis for compensation set by the Board of Directors, not the CEO. Said plainly, he was partially paid with “funny money” that gained value if he performed well and lost value if he didn’t. MNKD was selling sub $1 when Mike started. And as Steven Binder mentioned in the earnings call yesterday, MannKinds future was in doubt. 7 years later MannKind is prepared to be debt-free (an uncommon accomplishment for any company or government) and is even profitable, and the stock is selling somewhere between 4x and 5x of when Mike started. Many of us here feel grateful for the substantial effort that not only rescued our investment but has it on the verge of thriving. Two words... Reverse Split. Now, Unreverse the split and where are you at? Every shareholder is not at the same comfort level of being able to react/recover from that type of circumstance. I agree and can share the sentiment. Even with DCA post RS, I’m nowhwere near where I’d like to be 11 years after buying my first shares of MNKD. Even so, what does that have to do with whether the current set of executive management are fairly compensated, or whether their performance has been sufficient to reverse the fortunes of a moribund investment? |
|
|
|
Post by agedhippie on May 10, 2024 8:13:38 GMT -5
Where to start. 175 compared metformin. In fact in one arm we had metofrmin alone. In the other we had afrezza added to metformin. ... ROFL. You entirely made that up. Read the filing ( classic.clinicaltrials.gov/ct2/show/NCT01451398) and point at the metformin only arm. Nice try though.  |
|
|
|
Post by akemp3000 on May 10, 2024 9:03:22 GMT -5
The share price reacted negatively to very good 1Q results being reported. Explanations were that the forthcoming better news is still a year or two away. That, however was just as much true before the 1Q report as afterwards so that's not a valid explanation for the subsequent drop. IMO, the only thing that's logical is that some buyers got in hoping for a quick move up and when it didn't happen, they got back out. If so, this might happen again but at the rate MNKD is increasing revenue and earnings, prior patterns and short-term trading strategies will soon be out the window so to speak. Would be interested to learn what short-term traders expect to see regarding this.
|
|
|
|
Post by ktim on May 10, 2024 9:47:32 GMT -5
The share price reacted negatively to very good 1Q results being reported. Explanations were that the forthcoming better news is still a year or two away. That, however was just as much true before the 1Q report as afterwards so that's not a valid explanation for the subsequent drop. IMO, the only thing that's logical is that some buyers got in hoping for a quick move up and when it didn't happen, they got back out. If so, this might happen again but at the rate MNKD is increasing revenue and earnings, prior patterns and short-term trading strategies will soon be out the window so to speak. Would be interested to learn what short-term traders expect to see regarding this. I've traded around a much larger core position with the earnings swings. I don't presume to know the future. It works until it doesn't. |
|
|
|
Post by sayhey24 on May 10, 2024 10:19:02 GMT -5
Let me explain this for you. Using Afrezza for gestational diabetes is off-label since it is not approved for use during pregnancy. My bet is that some endos are using it in those cases just as some are prescribing for kids, most are not going to prescribe off-label which means a large scale clinical trial. Afrezza has never been evaluated against metformin. Like GLP-1 and every other insulin in the world Afrezza has been evaluated for cases where oral meds including metformin have failed, and like all those other injectables it was superior. No surprise. I believe that buying V-Go was about buying a revenue stream and a salesforce, nothing more. Nobody could have expected to turn around V-Go after two companies had tried and failed. It did make the books and story better however at a time when that was needed. I agree with your V-Go analysis but I also think Mike saw it as a platform device. I believe he wanted to use V-Go for other drugs that are needed on a daily basis. It could still happen but it's dragging down margins. One thing we have learned about Mike is there are a lot of head fakes starting with the shareholder meeting which ended up being something else with Damon Dash. Mike did say they were looking into other uses for the device. IMO, a head fake. Maybe its me but I took one look at the device and wrote that off. I think the reason V-Go was bought was to take the pressure off addressing the T2 market with afrezza. He still doesn't know how. We have no insurance. We have not done the needed studies. GLP1s are seeing a 1.5 - 2% A1C reduction and its really hard to argue about the weight loss GLP1s are seeing. Mike had no good answers so he said - afrezza is for T1s and V-Go is for T2s. |
|
|
|
Post by sayhey24 on May 10, 2024 10:25:26 GMT -5
Where to start. 175 compared metformin. In fact in one arm we had metofrmin alone. In the other we had afrezza added to metformin. ... ROFL. You entirely made that up. Read the filing ( classic.clinicaltrials.gov/ct2/show/NCT01451398) and point at the metformin only arm. Nice try though. OK - Metformin Only 42 participants and then 40 for afrezza and metformin. You want more? Its not going to matter. Metformin will still lose. It could be 42,000 and it will still lose. Are you trying to tell us Metformin will beat afrezza? |
|
|
|
Post by cretin11 on May 10, 2024 10:32:03 GMT -5
I agree with your V-Go analysis but I also think Mike saw it as a platform device. I believe he wanted to use V-Go for other drugs that are needed on a daily basis. It could still happen but it's dragging down margins. One thing we have learned about Mike is there are a lot of head fakes starting with the shareholder meeting which ended up being something else with Damon Dash. Mike did say they were looking into other uses for the device. IMO, a head fake. Was it an intentional head fake or just a miscalculation? My guess is the latter. Perhaps Zealand sold him on the concept and he bought it. Who knows about that, but we do know Zealand stock tripled immediately after unloading VGo on us, so they made out quite well in the deal. |
|
|
|
Post by agedhippie on May 10, 2024 10:59:43 GMT -5
OK - Metformin Only 42 participants and then 40 for afrezza and metformin. You want more? Its not going to matter. Metformin will still lose. It could be 42,000 and it will still lose. Are you trying to tell us Metformin will beat afrezza? So we are agreed that there never been a trial between metformin only and Afrezza, and that the 175 trial had people on multiple oral meds? |
|
|
|
Post by sayhey24 on May 10, 2024 11:08:08 GMT -5
OK - Metformin Only 42 participants and then 40 for afrezza and metformin. You want more? Its not going to matter. Metformin will still lose. It could be 42,000 and it will still lose. Are you trying to tell us Metformin will beat afrezza? So we are agreed that there never been a trial between metformin only and Afrezza, and that the 175 trial had people on multiple oral meds? Do you not understand the 175 trial? The bottom line is afrezza is superior to metformin and metformin plus a bunch of other meds. |
|
|
|
Post by prcgorman2 on May 10, 2024 11:11:23 GMT -5
One thing we have learned about Mike is there are a lot of head fakes starting with the shareholder meeting which ended up being something else with Damon Dash. Mike did say they were looking into other uses for the device. IMO, a head fake. Was it an intentional head fake or just a miscalculation? My guess is the latter. Perhaps Zealand sold him on the concept and he bought it. Who knows about that, but we do know Zealand stock tripled immediately after unloading VGo on us, so they made out quite well in the deal. While I agree Mike was definitely involved in the decision to acquire V-Go, it is not a good assumption Mike has carte blanche authorization to acquire companies completely on his own discretion.
If Mike was sold on V-Go, he wasn't the only one. |
|
|
|
Post by cretin11 on May 10, 2024 11:14:10 GMT -5
Interesting point. I wonder who is the primary person to instigate such a decision? Agree it shouldn't be any single person alone, but my guess is MC is the primary driver of such an acquisition. I'd like to know the dynamics of it, and would be curious to know if anyone tried to warn him not to do it. I don't expect we'll ever get such details.
|
|
|
|
Post by prcgorman2 on May 10, 2024 11:40:09 GMT -5
Interesting point. I wonder who is the primary person to instigate such a decision? Agree it shouldn't be any single person alone, but my guess is MC is the primary driver of such an acquisition. I'd like to know the dynamics of it, and would be curious to know if anyone tried to warn him not to do it. I don't expect we'll ever get such details. Agree, you're going to have to live with some mystery. What we know is Dr. Kendall is widely respected and went to Zealand and may have had some influence in the offer, consideration, and decision. I'm ok with that. I could not care less about V-Go. $20M for some trained salespeople and access to new customers might be more than should be spent, but it isn't simply a loss, and in comparison to other things, it is simply noise. Nobody shoots 100% from the free throw line. |
|
|
|
Post by celo on May 10, 2024 11:56:50 GMT -5
One thing we have learned about Mike is there are a lot of head fakes starting with the shareholder meeting which ended up being something else with Damon Dash. Mike did say they were looking into other uses for the device. IMO, a head fake. Was it an intentional head fake or just a miscalculation? My guess is the latter. Perhaps Zealand sold him on the concept and he bought it. Who knows about that, but we do know Zealand stock tripled immediately after unloading VGo on us, so they made out quite well in the deal. Easy with the immediately. It took a year and it wasn't a large sale by Zealand. At that time, it would have been great to sell my mannkind and purchase Zealand. They have done well since May 2022 |
|
|
|
Post by cretin11 on May 10, 2024 12:25:39 GMT -5
Yeah i guess Kendall could've used his intel to help Zealand pull off that coup, but still it's gotta be MC who signed off on it on our side, and my guess is negotiated it.
|
|
